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1. Introduction
The prevalence of diabetes, especially type 2 diabetes and hypertension are significantly
increased with the prevalence of obesity (Figures 1, 2 and 3) [1, 2]. Type 2 diabetes, hyperten‐
sion frequently associated with type 2 diabetes, and obesity are important risk factors for
cardiovascular morbidity and mortality and cardiac- and renal complications. Hyperglycemia
as well as hyperinsulinemia in type 2 diabetes is a cardiovascular risk by itself [3]. Type 2
diabetes, hypertension and obesity are characterized by stimulation of the renin-angiotensin-
aldosterone system (RAAS), elevated sympathetic activity and insulin resistance. Importantly,
these characteristics, themselves, are one of the cardiovascular risks. Therefore, pharmacolog‐
ical and non-pharmacological treatments for type 2 diabetes should be selected from favour‐
able effects on stimulated RAAS, elevated sympathetic nervous system activity, insulin
resistance and leptin resistance.
Weight loss is recommended to delay and prevent type 2 diabetes in obesity, and for the
treatment. Lifestyle modification such as a caloric restricted diet, reducing sedentary behav‐
iour and an increase in exercise form the basis of all therapy. Weight loss treated with lifestyle
modification including calorie restriction and/or exercise causes normalization of stimulated
RAAS, sympathetic activation, insulin resistance, and hyperleptinemia, which are usually
observed in type 2 diabetes and obesity. Recently, Straznicky et al. [4] and Masuo et al. [5] have
shown the low caloric diet and exercise have different effects on insulin resistance, the RAAS,
and sympathetic nervous activity in obese hypertensive subjects, although similar weight loss
was observed between both interventions. Straznicky et al. [4] reported that exercise had
stronger effects of normalized the RAAS stimulation, sympathetic activation and insulin
resistance compared to diet only, whereas Masuo et al. [5] showed mild calorie restriction and
mild exercise has different mechanisms on weight loss (normalization on sympathetic
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activation for mild calorie restriction, and normalization on insulin resistance for exercise).
The observations, however, demonstrate that a combination therapy for weight loss with a
low caloric diet and exercise is recommended for weight loss due to stronger suppression of
insulin resistance and sympathetic activation, which both are known as strong risk factors for
cardiovascular events. Although few studies have observed changes in body weight, blood
pressure, neurohormonal changes over a long duration such as 2 years, Masuo et al. [6]
observed more than 30% individuals who initially succeeded to significantly lose weight, had
rebound weight gain over 2 years. Understanding mechanisms underlying both type 2 diabetes
and obesity may help to achieve weight loss and maintenance of weight loss and the stricter
blood glucose goal. Maintenance of weight loss is another key factor to reduce cardiovascular
risks in type 2 diabetes in obesity [6].
In addition, most hypertensive patients with diabetes and obesity are very resistant to
controlling hypertension and frequently require two or more types of medications to achieve
blood pressure goals. Similarly, diabetic patients, especially type 2 diabetic patients with
obesity, need higher dose of anti-diabetic medications such as metformin or insulin. However,
pharmacological treatments for hypertension and diabetes with weight loss could reduce
pharmacological treatment [7, 8].
 
(a) Body mass index(a), Men 
(b) Body Mass index(a), Women 
Source: National Health Survey, Australian Bureau of Statics in 2008.
Prevalence of overweight and obesity has increased in both genders.
Figure 1. Overweight/obesity has increased in both genders in Australia [Source. Australian Bureau of Statics. 4819.0.
Released at 11:30 AM (CANBERRA TIME) 25/01/2008] Reference [1]
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The purpose of this review is to provide, i) the importance of lifestyle modifications to delay
and prevent type 2 diabetes, ii) Lifestyle modification to reduce cardiovascular risks in type 2
diabetes, and iii) weight loss for the better pharmacological control on type 2 diabetes and
hypertension, which frequently co-exist with type 2 diabetes. iv) The mode of weight loss
influences different physiological pathways, with calorie restriction and exercise program. v)
Different mechanisms may contribute to reductions in blood pressure and cardiovascular risks
associated with weight loss with the relevant physiological mechanisms at play being de‐
pendent on the mode of weight loss.
2. Type 2 diabetes versus Type 1 diabetes
Prevalence of diabetes has increased markedly over the last 20 years in parallel with obesity
(Figures 2 and 3) [1, 2]. As of 2010 there are approximately 285 million people with the disease
compared to around 30 million in 1985. Long-term complications from high blood sugar can
include heart disease, strokes, renal failure, diabetic retinopathy, and diabetic neuropathy.
 
Figure 2. Prevalence of diabetes has increased in parallel with obesity. [Reference 2]
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Diabetes mellitus includes type 2 diabetes (formerly noninsulin dependent diabetes), type 1
diabetes (formerly insulin dependent diabetes), and gestational diabetes. These 3 types of
diabetes have different characteristics and progress [9]. Ninety percent of diabetic patients are
type 2 diabetes and the other 10% are due primarily to diabetes mellitus type 1 and gestational
diabetes.
2.1. Diabetes mellitus type 2 (Formerly noninsulin-dependent diabetes mellitus (NIDDM))
Type 2 diabetes is the most common form of diabetes, affecting 90% of all patients with
diabetes. This type of diabetes is characterised by metabolic disorder with insulin resistance
and relative insulin deficiency [10]. This is in contrast to type 1 diabetes, in which there is an
absolute insulin deficiency due to destruction of islet cells in the pancreas [9, 11]. Obesity is
thought to be the primary cause of type 2 diabetes in people who are genetically predisposed
 Type 2 Diabetes 
Prevalence of Cardiovascular Diseases 
Prevalence of hyperlipidemia 
Figure 3. Prevalence of type 2 diabetes, cardiovascular disease and hyperlipidemia (hyper cholesterolemia) increased
with obesity in both genders. [Source: National Health Survey, Australia, 2004-2005] Reference [1]
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to the disease, and obesity has been found to contribute to approximately 55% of case of type
2 diabetes [12].
The disease is strongly genetic in origin but lifestyle factors such as excess weight, inactivity,
high blood pressure and poor diet are major risk factors for its development. Symptoms may
not show for many years and, by the time they appear, significant problems may have
developed. People with type 2 diabetes are twice as likely to suffer cardiovascular disease. The
classic symptoms are excess thirst, frequent urination, and constant hunger.
Type 2 diabetes is initially managed by increasing exercise and dietary modification. If blood
glucose levels are not adequately lowered by these measures, medications such as metformin
or insulin may be needed. In those on insulin, there is typically the requirement to routinely
check blood sugar levels.
2.2. Type 1 diabetes (Insulin-dependent diabetes)
Type 1 diabetes is an auto-immune disease targeting on the insulin-producing beta cells in the
pancreas. This type of diabetes, also known as juvenile-onset diabetes, accounts for approxi‐
mately 10% of all people with the disease. In the majority of cases this type of diabetes appears
before the patient is 40 years old, triggered by environmental factors such as viruses, diet or
chemicals in people genetically predisposed. Patients with type 1 diabetes will require insulin
therapy regularly, and should follow a careful diet and exercise plan.
2.3. Gestational diabetes mellitus
Gestational diabetes, or glucose intolerance, is first diagnosed during pregnancy through an
oral glucose tolerance test. Between 5.5 and 8.8% of pregnant women develop gestational
diabetes in Australia [13], and 2 to 10 percent of all pregnancies in USA [14]. The hormones
produced during pregnancy increase the amount of insulin needed to control blood glucose
levels. If the body can’t meet this increased need for insulin, women can develop gestational
diabetes during the late stages of pregnancy.
While the glucose intolerance usually returns to normal after the birth, the mother has a
significant risk of developing permanent diabetes while the baby is more likely to develop
obesity and impaired glucose tolerance and/or diabetes later in life [15]. Risk factors for
gestational diabetes include a family history of diabetes, increasing maternal age, obesity, lack
of sleep [16], and being a member of a community or ethnic group with a high risk of devel‐
oping type 2 diabetes. Self-care and dietary changes are essential in treatment.
3. Prevalence of type 2 diabetes
The prevalence of type 2 diabetes has dramatically increased in parallel in rising prevalence
of obesity (Figures 1 and 2), and it increases with obesity (Figure 3). Rates of diabetes in 1985
in worldwide were estimated at 30 million, increasing to 135 million in 1995 and 217 million
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Type 1 Diabetes Type 2 Diabetes
Diagnosis: Genetic, environmental and auto-immune factors,
idiopathic
Genetic, obesity (central adipose), physical inactivity,
high/low birth weight, GDM, poor placental growth,
metabolic syndrome
Warning Signs: Increased thirst & urination, constant hunger,
weight loss, blurred vision and extreme tiredness,
glycouria
Feeling tired or ill, frequent urination (especially at
night), unusual thirst, weight loss, blurred vision,
frequent infections and slow wound healing,
asymptomatic
Target Groups: Children/teens Adults, elderly, ethnic groups
Prone ethnic groups: All more common in African American, Latino/Hispanic,
indigenous, Asian or Pacific Islander
Bodily Effects: Believed to be triggered autoimmune destruction of
the beta cells; autoimmune attack may occur
following a viral infection such as mumps, rubella
cytomegalovirus
Appears to be related to aging, sedentary life-style,
genetic influence, but mostly obesity
Common physical attributes
found:
Mostly Normal or Thin Mostly Overweight or Obese
You have this when: Your body makes too little or no insulin. Your body either cannot produce insulin or does not
use it properly.
Estimated percentage of
occurrence:
5% -10% of the 171 million of people affected by
diabetes in 2000
90% - 95%-of total cases. Although the projected
number of Americans that will have type II diabetes
in the year 2030 will double from 171 million to 366
million cases
Affected age group: Between 5 - 25 (maximum numbers in this age
group; Type 1 can affect at any age)
Until recently, the only type of diabetes that was
common in children was Type 1 diabetes, most
children who have Type 2 diabetes have a family
history of diabetes, are overweight, and are not very
physically active. Usually develops around puberty
Glucose Channels/receptors: Open and absorb glucose into cell to be utilized by
processes after the induction of insulin
Are unable to open and absorb glucose, therefore
glucose cannot be utilized by processes; as a result
the glucose stays in the blood stream
Cure: None Physical exercise, healthy loss of weight & diet
control
Treatment: Insulin Injections, dietary plan, regular check up of
blood sugar levels, daily exercise Goals: optimal
glucose, prevent/treat chronic complications,
enhance health with food/PA, individual nutrition
needs
Diet, exercise, weight loss, and in many cases
medication. Insulin Injections may also be used,
SMBG
Dependency: Insulin-dependent Not insulin-dependent
Onset: Rapid (weeks) Slow (years)
[Reference, American Diabetes Association-Executive Summary-2012, A-348]
Table 1. Comparison between type 1 diabetes and type 2 diabetes
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in 2005 [17]. This increase is believed to be primarily due to the global population aging, a
decrease in exercise, and increasing rates of obesity [18].
The prevalence of diabetes is recognized as a global epidemic by the World Health Organiza‐
tion (WHO) [19]. The World Health Organization (WHO) has reported 346 million people
worldwide had diabetes in 2004. Globally as of 2010 it was estimated that there were 285 million
people with type 2 diabetes, and this is equivalent to about 6% of the world’s adult population
[18]. In 2010, diabetic patients were estimated as 316 million people worldwide, and this is
equivalent to about 6% of the world’s adult population. Importantly, the National Diabetes
Fact Sheet 2011 by Centers for Disease Control and Prevention (CDC) pointed out 7.0 million
American people (27% of those with diabetes) were not diagnosed and an estimated 79 million
Americans have pre-diabetes, indication that much more of the population were affected by
diabetes [20, 21]. An estimated 3.4 million people died from consequences of diabetes in 2004,
which more than 80% of diabetes deaths occurs in low- and middle-income countries, and
diabetes deaths will increase by double between 2005 and 2030 [22]. The five countries with
the greatest number of people with diabetes as of 2000 are India, China, the United States,
Indonesia, and Japan. Diabetes is common both in the developed and the developing world,
but not in the underdeveloped world. Women seem to be at a greater risk as do certain ethnic
groups such as South Asians, Pacific Islanders, Latinos, and Native Americans [18]. This may
be due to enhanced sensitivity to a Western lifestyle in certain ethnic groups [23].
4. What causes type 2 diabetes?
Many epidemiological studies showed a strong association between obesity and type 2
diabetes, however it is also true that not all obese individuals have type 2 diabetes [20]. Majority
of the onset and development of type 2 diabetes is caused by a combination of lifestyle and
genetics. Other confounders are also reported to relate to the onset and development of type
2 diabetes: i.e. lack of sleep [16], which has been linked to type 2 diabetes through its effect on
metabolism [15], nutritional status of a mother during fetal development may also play a role,
with one proposed mechanism being that of altered DNA methylation [24]. While some are
under personal control, such as diet and obesity, others, such as increasing age, female gender,
and genetic susceptibility, is not. The followings are several causes known for type 2 diabetes.
4.1. Lifestyle
A number of lifestyle factors are known to be important to the development of type 2 diabetes,
including obesity, lack of physical activity (sedentary life style) [12], poor diet, stress, and
urbanization.
Excess body fat is associated with 30% of cases in type 2 diabetes of Chinese and Japanese
descent, 60-80% of cases in those of European and African descent, and 100% of Pima Indians
and Pacific Islanders [19, 23]. Interestingly, Pima Indians and Pacific Islanders have relatively
higher waist-to-hip ratio even if they are not obese, suggesting that abdominal obesity and
visceral fat is more important to cause type 2 diabetes.
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Dietary factors also influence the risk of developing type 2 diabetes. Consumption of sugar-
sweetened drinks in excess is associated with an increased risk. It has been demonstrated
saturated fat and trans-fatty acids increase LDL cholesterol, the risk of type 2 diabetes, and
cardiovascular risk. Poly-unsaturated, and monounsaturated fat decreasing the risk, but It is
recommended to take both in a limited quantity. The American Heart Association has
recommended that Americans should limit their intake of saturated fats to 7% of their total
calories in a day, while unsaturated fats can form 30% of the calorie intake.
4.2. Genetics
Most cases of diabetes involve many genes, with each being a small contributor to an increased
probability of becoming a type 2 diabetic. If one identical twin has diabetes, the chance of the
other developing diabetes within his lifetime is greater than 90% while the rate for non-
identical siblings is 25-50%. As of 2011, more than 36 genes have been found that contribute
to the risk of type 2 diabetes. All of these genes together still only account for 10% of the total
heritable component of the disease. The TCF7L2 allele, for example, increases the risk of
developing diabetes by 1.5 times and is the greatest risk of the common genetic variants. Most
of the genes linked to diabetes are involved in beta cell functions in pancreas.
There are a number of rare cases of diabetes that arise due to an abnormality in a single gene
(known as monogenic forms of diabetes or "other specific types of diabetes"). These include
maturity onset diabetes of the young (MODY), Donohue syndrome, and Rabson-Mendenhall
syndrome, among others. Maturity onset diabetes of the young constitutes 1–5% of all cases
of diabetes in young people.
4.3. Medical conditions
There are a number of medications, including glucocorticoids, thiazides, beta blockers, atypical
antipsychotics, and statins that can predispose to diabetes [25].
Statins have beneficial effects on reductions of cardiovascular risks through lipids control, and
mortality and morbidity in patients with high cardiac risk such as diabetes, coronary heart
disease, ischemic heart disease, chronic kidney disease, chronic heart failure, and peripheral
vascular disease [26, 27]. National and international clinical guidelines in the management of
these cardiovascular disease conditions all advocate for the utilization of statins therapy in
appropriate patients. The meta-analysis including 80,771 participants with low cardiac risk
showed that all-cause mortality was significantly lower among patients receiving a statin than
among controls with a 10-year risk of cardiovascular disease < 20% [28]. Patients in the statin
group were also significantly less likely than controls to have nonfatal myocardial infarction,
and nonfatal stroke, but the effects did not depend on high- and low-potency statins, or larger
reductions in cholesterol. The JUPITER trial [27] and Atherosclerosis Risk in Communities
(ARIC) Study [29] demonstrated that suppression of low-grade inflammation by statins
improves these clinical outcomes.
Recently, concerns were raised regarding the onset and development of diabetes in statin-
treated patients [30]. The meta-analysis studied by Coleman et al. [31] showed that statins, as
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a class, did not demonstrate a statistically significant positive or negative impact on a patient's
risk of developing new-onset type 2 diabetes mellitus, whereas Satter et al. [32] observed that
statin therapy is associated with a slightly increased risk of development of diabetes using
meta-analysis, but the risk is low both in absolute terms and when compared with the
reduction in coronary events. Clinical practice in patients with moderate or high cardiovas‐
cular risk or existing cardiovascular disease should not change. In 2012, two major studies
have addressed the question of whether statins lead to an increase in diabetes, which included
the meta-analysis of 33,000 participants enrolled in 5 major clinical trials using statins [33, 34],
and analysed data from 153,840 postmenopausal women between 50 and 80 years in the
Women Health Initiative Study [30]. The study showed women taking statins had a 48%
increased risk of diabetes compared those without statins. The American Heart Association
concluded in 2012 that the benefits of statins on lipids-lowering effects and resultant reductions
in cardiovascular risks overweighted to the new onset or development of diabetes [35].
Combined bezafibrate/statin therapy is theoretically believed more effective in achieving a
comprehensive lipid control and residual cardiovascular risk reduction [36, 37]. The ACCORD
Study [38], however, showed that the combination of fenofibrate and simvastatin did not
reduce the rate of fatal cardiovascular events, nonfatal myocardial infarction, or nonfatal
stroke, as compared with simvastatin alone. Based on the beneficial effects of pan-PPAR
agonist bezafibrate on glucose metabolism and prevention of new-onset diabetes, one could
expect a neutralization of the adverse pro-diabetic effect of statins using the strategy of a
combined statin/fibrate therapy [39, 40].
5. Type 2 diabetes mellitus as a risk factor for cardiovascular disease
Several epidemiological studies are available to understand that diabetes is a strong cardio‐
vascular disease risks. A population-based European Prospective Investigation into Cancer
and Nutrition (EPIC)-Potsdam study [41], which consisted of 23,455 participants (9,729 men
and 15,438 women) followed up from 1994-1998 to 2006, showed that participants with a high
risk of the development of diabetes had significantly higher risks of myocardial infarction and
stroke than those with a low risk of diabetes development. Subjects at a high risk of diabetes
development were also at considerably higher risks of developing cardiovascular complica‐
tions in general.
The Framingham Heart Study [42] observed that both cardiovascular disease and non-
cardiovascular disease mortality rates among individuals with diabetes mellitus were
approximately 2-fold higher compared with individuals without diabetes. Non-cardiovascu‐
lar disease mortality declined among women without diabetes mellitus, while no change in
non-cardiovascular disease mortality was observed among women and men with diabetes
between the “1950 to 1975” and “1976 to 2001” period. Importantly, individuals with diabetes
were at a higher risk of all-cause mortality, especially cardiovascular disease mortality, in both
the periods compared to those without diabetes. Another study has shown that diabetes is
associated with a substantial increase in all cause and coronary heart disease mortality [43].
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Regarding the gender differences in mortality and morbidity of cardiovascular complications,
Kanaya et al. [44], in their meta-analysis, documented that absolute coronary heart disease
death rates were higher in diabetic men compared with diabetic women at every age except
the very oldest, however, the excess relative risk of coronary heart disease mortality in women
versus men with diabetes was absent after adjusting for classic coronary heart disease risk
factors (i.e. dyslipidemia, hypertension).
Recently, the Detection of Ischemia in Asymptomatic Diabetics (DIAD) study [45] was
performed in 1,123 patients with type 2 diabetes and no symptoms of coronary heart disease
using adenosine-stress radionuclide myocardial perfusion imaging from 2000 to 2007. The
cumulative cardiac event rate in DIAD was 2.9% over a mean follow-up of 4.8 years for an
average of 0.6% per year, which is higher compared to the general population.
The World Health Organization Multinational Study of Vascular Disease in diabetes [46, 47]
examined the relationship between excess mortality and proteinuria/hypertension in a
stratified random sample of 4,714 diabetic patients aged 35-55 years from 1975 to 1987. Even
in the absence of proteinuria and hypertension, standardized mortality rates were significant
higher in patients with both type 1 and type 2 diabetes compared to the general population.
Standardized mortality was higher in those with type 1 diabetes compared with type 2
diabetes, and the standard mortality rate increased with increasing diabetes duration. In
addition, both hypertension and proteinuria had a strikingly high mortality risk by 11-fold for
men with type 1 diabetes, and 5 fold for men with type 2 diabetes, indicating that diabetes
accompanying cardiovascular disease leads to even higher mortality risk.
Hypertension is twice as frequent in diabetic patients in the general population, and its
prevalence is higher in type 2 diabetes than in type 1 diabetes. In type 2 diabetes, the onset of
hypertension often precedes the diagnosis of diabetes, whereas in type 1 diabetes it is strictly
related to the presence of nephropathy [48].
Further, many studies have shown the strong associations of myocardial infarction [49] and
atherosclerosis [50-52]. A number of epidemiological studies provide evidence that diabetes
mellitus is a significant risk factor for cardiovascular disease mortality and morbidity [53].
Longer duration of diabetes is a stronger predictor of mortality among diabetic patients.
Therefore, people who have diabetes mellitus or strong lifestyle or dietary factors to predict
the development of type 2 diabetes [54] should avoid the cardiovascular complications.
6. Neurohoromonal characteristics in type 2 diabetes: Insulin resistance
and sympathetic activity
It is widely recognized that insulin resistance is a major mechanism of the onset of type 2
diabetes. Insulin resistance in children could predict future glucose intolerance and type 2
diabetes in 10 years [46, 55]. Reduced energy expenditure and resting metabolic rate are
predictive of weight gain (obesity). The sympathetic nervous system participates in regulating
energy balance through thermogenesis. Many epidemiological and clinical studies have shown
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a close relationship between sympathetic nervous system activity and insulin levels in obesity
and in weight gain [56, 57]. Elevations of sympathetic nervous system activity and insulin
levels during weight gain [58-60] and reductions of sympathetic activity and insulin levels
during weight loss [61-64] are typically observed. In addition, The response of the sympathetic
nervous system to changes in plasma insulin levels after oral glucose loading (oral glucose
tolerance test) are different between subjects with and without insulin resistance [65], between
nonobese and obese subjects [66], and between subjects with and without metabolic syndrome
[67]. Those observations provide evidence of a strong linkage between the activity of the
sympathetic nervous system and insulin levels over glucose metabolisms. Straznicky et al. [68]
reported that the progress from metabolic syndrome to type 2 diabetes might be associated
with increased central sympathetic drive, blunted sympathetic responsiveness, and altered
norepinephrine disposition.
Acute hyperglycemia caused sympathetic activation and peripheral vasodilation. Moreover,
both acute and chronic hyperglycemia and hyperinsulinemia may enhance adrenergic
vasoconstriction and decrease vasodilation in animal models (pithed rats) [69, 70]. Insulin
causes forearm vasoconstriction in obese, insulin-resistant hypertensive humans [71]. On the
other hand, van Veen et al. [72] found that hyperglycemia in the forearm induced vasodilation,
but this vasodilation was not modified by hyperinsulinemia.
Huggett et al. [66] examined muscle sympathetic nerve activity (MSNA) in four groups of
subjects, patients with essential hypertension and type 2 diabetes, patients with type 2 diabetes
alone, patients with essential hypertension alone, and healthy normotensive controls. They
found higher MSNA in hypertensive-type 2 diabetic patients compared with hypertensive
alone patients or type 2 diabetic alone patients, and higher MSNA in hypertensive alone
patients or type 2 diabetic alone patients compared with healthy normotensive controls.
Fasting insulin levels were greater in hypertensive-type 2 diabetic patients and type 2 diabetic
patients compared to hypertensive patients or healthy normotensive subjects. These findings
provided evidence that type 2 diabetic patients had elevated sympathetic nerve activity
regardless of the prevailing blood pressure levels, and that the combination of hypertension
and type 2 diabetes resulted in an augmentation in sympathetic nerve activity and levels of
plasma insulin.
Moreover, stimulation of the renin-angiotensin-aldosterone system (RAAS) is frequently
demonstrated in type 2 diabetes [73], and may be related to insulin resistance either via direct
or indirect mechanisms [74].
7. Treatments for type 2 diabetes
Weight loss is recommended as the first line of treatment for type 2 diabetes and hypertension
associated with obesity, because obesity is the primary cause for insulin resistance, metabolic
syndrome and type 2 diabetes. Indeed, lifestyle modification including a low caloric diet,
reducing sedentary behaviour and exercise form the foundation of all therapy. For the subjects
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who are more severely obese or unable to undertake an exercise program, bariatric surgery is
recommended.
7.1. Lifestyle modification for weight loss
Weight loss is recommended as the first-line treatment for obesity-related type 2 diabetes and
hypertension. The objective of treatment for obesity, type 2 diabetes and hypertension is both
to reduce the high risk of cardiovascular events and to prevent or delay the onset of type 2
diabetes and complications. Lifestyle intervention with diet and exercise leading to weight loss
prevents and delays the onset of type 2 diabetes or glucose intolerance [75]. Weight loss may
also prevent cardiovascular- and renal-complications [76-79], and renal function and left
ventricular hypertrophy as a marker for future cardiac events in obese individuals with
metabolic syndrome and hypertension [77, 80]. The US Diabetes Prevention Program [81] and
the Oslo Diet and Exercise Study [82] have shown marked clinical benefits with lifestyle
intervention, and modest weight loss, on the resolution of the metabolic syndrome and type
2 diabetes. A limited number of epidemiological studies have shown that intentional weight
loss may be associated with increased mortality and fat loss may reduce the all-cause mortality
rate [83].
Cohort studies with lifestyle intervention [84] and case control studies with bariatric surgeries
[85, 86] also provide some evidence that intentional weight loss has long-term benefits on all
cause mortality in overweight adults. In a cohort of patients enrolled in a cardiac rehabilitation
program, weight loss was associated with favourable long-term outcomes on the composite
end-point of mortality and acute cardiovascular events (fatal and nonfatal myocardial
infarction, fatal and nonfatal stroke, emergent revascularization for unstable angina pectoris,
and congestive heart failure) [87].
Many clinical studies have demonstrated that weight loss associated with life-style modifica‐
tion adds to the first line treatment for diabetes mellitus and the efficacy of antihypertensive
pharmacological treatments [8], however, maintaining weight loss is often the greatest
challenge [5, 6, 88].
7.1.1. Calorie restricted diet versus aerobic exercise
The American Diabetes Association (ADA) has recommended for the maintenance of a healthy
weight to prevent and control diabetes as following; (i) more than 2.5 hours of exercise per
week, (ii) having a modest fat intake (approximately 30% of energy supply), and (iii) rating
sufficient fiber [89]. Recently, several investigations [4, 5, 90] compared the effects on weight
loss between calorie restriction (diet) and exercise. They showed that combined intervention
with diet and exercise proved to be effective in weight reduction than diet alone or exercise
alone. Masuo et al. [5] reported that the group with mild exercise alone had greater and faster
loss of total body fat-mass compared to the diet alone group, whereas Toji et al. [90] reported
that exercise intervention alone was not found to be effective on weight loss. There are
discordant results on the effects of diet and exercise on weight loss and weight loss-induced
blood pressure reductions, however many large cohort interventions and clinical studies have
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shown combination weight loss regimens with mild calorie restriction and mild exercise was
the most effective for significant weight loss compared to diet alone or exercise alone.
A low caloric diet and exercise exert different effects on insulin resistance, the RAAS, and
sympathetic nervous activity in obese hypertensive subjects, even though similar weight loss
was observed [4, 5]. Low caloric diet may be prominent for normalization of sympathetic
nervous activity and exercise may be related more to normalization of insulin resistance [5,
88] (Figure 4). They previously observed that baseline plasma norepinephrine levels could
predict future weight gain and weight gain-induced blood pressure elevation over 5 years in
a longitudinal study [91], resistant weight loss by weight loss intervention with combination
of calorie restriction and exercise intervention over 2 years. [6, 88] Similarly, Straznicky et al.
[92] showed baseline sympathetic tone measured by muscle sympathetic nervous activity and
nutritional responsiveness could predict the success of dietary weight loss, but not exercise,
supporting the results including that the sympathetic nervous activity plays major mecha‐
nisms and roles on diet-induced weight loss pointed by Masuo, et al. [5]. Ribeiro et al. [93],
Trombetta et al. [94] and Tonacio et al. [95] compared the effects of a low caloric diet and exercise
on blood pressure lowering and forearm blood flow. They observed that only exercise, not
diet, significantly increased forearm blood flow.
Santarpia et al. [96] reviewed the effectiveness of weight loss regimens and body composi‐
tion after weight loss between diet and exercise. At a long term follow up (over one year),
Figure 4: When significant changes were observed
comparisons between a calorie restricted diet vs. mild exercise alone vs. 
combination with diet + exercise over 24 weeks
Diet alone
0_______2_______4_______8________12______________________24 
weeks
Exercise alone
0_______2_______4_______8________12______________________24 
weeks
Combination with Diet and Exercise    
0_______2_______4_______8________12______________________24 
weeks
)
NE                     weight  Fat  SBP        DBP      
HOMA
HOMA Weight NE       SBP DBP
NE    Weight SBP         DBP
Fat HOMA
Fat
Reference [5]
NE, plasma norepinephrine as index of sympathetic activity;
HOMA, HOMA-IR (homeostasis model assessment of insulin resistance) as an index of insulin resistance; Weight, body
weight; Fat, total body fat-mass; SBP, systolic blood pressure;
DBP, diastolic blood pressure.
Figure 4. When significant chages were observed comparisons between a calorie restricted diet vs. mild exercise
alone vs. combination with diet + exercise over 24 weeks
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relatively high protein, moderately low calorie, low glycemic index diets, associated with a
daily, moderate intensity, physical exercise (of at least 30 min), appear to be more successful
in limiting long term rebound, maintaining fat-free-mass and achieving the highest fat loss.
Diet alone or physical exercise alone does not produce similar results. Adequate dietetic ad‐
vice plus regular physical exercise avoid the fat-free-mass loss usually observed in the re‐
bound of the weight cycling syndrome and prevent the onset of sarcopenic obesity.
Exercise training is important for weight loss and to prevent rebound weight gain after sig‐
nificant weight loss. Public health interventions promoting walking are likely to be the most
successful. Indeed, walking is unique because of its safety, accessibility, and popularity. It is
noteworthy that there is a clear dissociation between the adaptation of cardiopulmonary fit‐
ness and the improvements in the metabolic risk profile such as insulin resistance and sym‐
pathetic activation, which can be induced by endurance training programs. Dumortier et al.
[97] also reported that individualized low intensity endurance aerobic training improves lip‐
id oxidation, body composition and insulin resistance. It appears that as long as the increase
in energy expenditure is sufficient, low-intensity endurance exercise is likely to generate
beneficial metabolic effects that would be essentially similar to those produced by high-in‐
tensity exercise [98]. The clinician should therefore focus on the improvement of the meta‐
bolic profile rather than on weight loss alone [98].
7.1.2. Dietary
7.1.2.1. Saturated fat versus unsaturated fat
Recently, several large cohort studies have shown that saturated fat, which comes mainly
from animal sources of food, raises LDL cholesterol and links strongly to cardiovascular risk
[99, 100]. Saturated fats are needed for the production of hormones, the stabilization of cellu‐
lar membranes, the padding around organs, and for energy. A deficiency in the consump‐
tion of saturated fats can lead to age-related declines in white blood cell function, along with
dysfunction of the immune system and cancer [101]; however, a high content of saturated
fat can leads to coronary heart disease [102], ischemic heart disease, and atherosclerosis and
increase the chances of stroke.
Consistent evidence from prospective observational studies of habitual trans fatty acids
(TFA) consumption and retrospective observational studies using TFA biomarkers indicates
that TFA consumption increases risk of clinical coronary heart disease, and other disease
outcomes such as cancer [102].
Unsaturated fats are known to increase the levels of High Density Lipoprotein (HDL choles‐
terol) and hence decrease LDL and VLDL cholesterol. Both types of unsaturated fat- mono-
unsaturated and poly-unsaturated fats can replace saturated fats in the diet. Substituting
saturated fats with unsaturated fats help to lower levels of total cholesterol and LDL cholesterol
in the blood. However, intake of unsaturated fats in very high amounts can also increase the
risk of coronary heart diseases.
i. Monounsaturated fat: This is a type of fat found in a variety of foods and oils. Studies
show that eating foods rich in monounsaturated fats (MUFAs) improves blood
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cholesterol levels, which can decrease the risk of heart disease. Research also shows
that MUFAs may benefit insulin levels and blood sugar control, which can be
especially helpful for type 2 diabetes.
ii. Polyunsaturated fat (PUFAs): This is a type of fat found mostly in plant-based foods
and oils. The Swedish Mammography Cohort study including 34, 670 women with
a mean follow-up of 10.4 years, showed that intake of long-chain omega-3 PUFAs is
inversely associated with risk of stroke, whereas dietary cholesterol is positively
associated with risk [103]. Similarly, Chowdhury et al. [104] observed in meta-analysis
that moderate, inverse associations of fish consumption and long chain omega 3 fatty
acids with cerebrovascular risk, but long chain omega 3 fatty acids measured as
circulating biomarkers in observational studies or supplements in primary and
secondary prevention trials were not associated with cerebrovascular disease. The
beneficial effect of fish intake on cerebrovascular risk is likely to be mediated through
the interplay of a wide range of nutrients abundant in fish. PUFAs decrease the risk
of type 2 diabetes. One type of polyunsaturated fat, a long chain omega-3 fatty acids
is especially beneficial to coronary heart disease.
iii. Trans-fatty acids (TFA): Growing evidence indicates that trans-fatty acids (TFA)
adversely affect cardiovascular health. Controlled trials and observational studies
provide concordant evidence that consumption of TFA from partially hydrogenated
oils adversely affects multiple cardiovascular risk factors, and contributes signifi‐
cantly to increased risk of coronary heart disease events. The public health implica‐
tions of ruminant TFA consumption appear much more limited. Nurses’ health study
showed that trans-fat intake was associated with increased risk of coronary heart
disease, particularly for younger women [105]. Interestingly, incidence of insulin
resistance is lowered with diets higher in monounsaturated fats (especially oleic acid),
while the opposite is true for diets high in polyunsaturated fats (especially large
amounts of arachidonic acid) as well as saturated fats. This relationship between
dietary fats and insulin resistance is presumed secondary to the relationship between
insulin resistance and inflammation, which is partially modulated by dietary fat
ratios (Omega3/6/9) with both omega 3 and 9 thought to be anti-inflammatory, and
omega 6 pro-inflammatory [106].
It is recommended to take both in a limited quantity. The American Heart Association has
recommended that Americans should limit their intake of saturated fats to 7% of their total
calories in a day, while unsaturated fats can form 30% of the calorie intake to reduced cardi‐
ovascular risks.
7.1.2.2. Special diet
i. Low Carbohydrate Diet
Low-carbohydrate diets are dietary programs that restrict carbohydrate consumption usually
for weight control or for the treatment of obesity. The term "low-carbohydrate diet" is generally
applied to diets that restrict carbohydrates to less than 20% of caloric intake, but can also refer
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to diets that simply restrict or limit carbohydrates. Recently, the low carbohydrate diets has
been spotlighted due to strong effects on weight loss, but many investigations have also shown
no benefits on the reductions on cardiovascular risk as the major aim of weight loss.
A study of more than 100,000 people over more than 20 years within “the Nurses' Health
Study” observationally concluded that a low-carbohydrate diet high in vegetables, with a large
proportion of proteins and oils coming from plant sources, decreases mortality with a hazard
ratio of 0.8. In contrast, a low-carbohydrate diet with largely animal sources of protein and fat
increases mortality, with a hazard ratio of 1.1, although there were criticisms on the methods
[107]. A 2003 meta-analysis that included randomized controlled trials found that "low-carbo‐
hydrate, non-energy-restricted diets, appear to be at least as effective as low-fat, energy-re‐
stricted diets in inducing weight loss for up to 1 year [108]. Gardner et al. [109] compared the 4
special diet including the Atkins (a low-carbohydrate), Zone (by Barry Sears PhD, 40% carbo‐
hydrates, 30% protein, and 30% fats), Ornish (very low fat diet), and LEARN diets (55% to 60%
energy from carbohydrate and less than 10% energy from saturated fat) to evaluate the effects
of weight loss, metabolic effects and the risk over 1 year in 311 obese, non-diabetic, premeno‐
pausal women with randomized design. Weight loss was significantly greater for women in
the Atkins diet group (low carbohydrate) compared with the other 3 diet groups at 12 months,
and weight loss in the other 3 groups were similar, but at 12 months, secondary outcomes for
the Atkins group were more favorable metabolic effects than the other diet groups. While ques‐
tions remain about long-term effects and mechanisms, a low-carbohydrate, high-protein, high-
fat diet may be considered a feasible alternative recommendation for weight loss. However,
some investigators suggested that that one of the reasons people lose weight on low carbohy‐
drate diet is related to the phenomenon of spontaneous reduction in food intake [110].
Previously, in routine practice a reduced-carbohydrate, higher protein diet was recommended
approach to reducing the risk of cardiovascular disease and type 2 diabetes [111]. In 2004, the
American Diabetes Association (ADA) affirmed its acceptance of carbohydrate-controlled
diets as an effective treatment for short-term (up to one year) weight loss among obese people
suffering from type 2 diabetes [112]. And the American Diabetes Association (ADA) revised
their “Nutrition Recommendations and Interventions for Diabetes in 2008” to acknowledge low-
carbohydrate diets as a legitimate weight-loss plan [113]. The recommendation, however, fell
short of endorsing low-carbohydrate diets as a long-term health plan nor do they give any
preference to these diets. On the other hand, the official statement from the American Heart
Association (AHA) regarding these diets states categorically that the association doesn't
recommend high-protein diets [35]. A science advisory from the AHA further states the
association's belief that these diets are associated with increased risk for coronary heart disease
[114, 115]. The AHA has been one of the most adamant opponents of low-carbohydrate diets.
The American Heart Association supported low-fat and low-saturated-fat diets, but that a low-
carbohydrate diet could not potentially meet AHA guidelines.
ii. Low fat diet
Recently, the effectiveness of low-fat high- protein and low-fat high-carbohydrate dietary
advice on weight loss were compared using group-based interventions, among overweight
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people with type 2 diabetes. However, in a 'real-world' setting, prescription of an energy-
reduced low-fat diet, with either increased protein or carbohydrate, results in similar modest
losses in weight, waist circumference and metabolic benefits over 2 years [116].
Ebbeling et al. [117] investigated the effect of dietary composition on energy expenditure
during weight-loss maintenance among the 3 different diet groups (low-fat diet, low-glycemic
index diet, and very low carbohydrate diet) with a controlled 3-way crossover design involving
21 overweight and obese young adults each for 4 weeks. Resting energy expenditure (REE),
total energy expenditure (TEE), hormone levels, and metabolic syndrome components at pre-
weight-loss were compared. Decreases in REE and TEE following 10% or 15% weight loss were
greatest with the low-fat diet, intermediate with the low-glycemic index diet, and least with
the very low-carbohydrate diet, but metabolic or hormonal parameters were similar between
3 groups.
iii. Low glycemic index
The concept of the glycemic index was developed about 1981 by Dr. David Jenkins to account
for variances in speed of digestion of carbohydrates. This concept classifies foods according
to the rapidity of their effect on blood sugar levels – with fast digesting simple carbohydrates
causing a sharper increase and slower digesting complex carbohydrates such as whole grains
a slower one. The concept has been extended to include amount of carbohydrate actually
absorbed as well, despite differences in glycemic index [118].
7.2. Pharmacological treatments for type 2 diabetes
If the individuals failed to improve glucose levels or HbA1c, pharmacological therapy is
required. The first-line oral agents should minimize the degree of insulin resistance and
suppress hepatic glucose production rather than increase plasma insulin concentrations. The
decision to include thiazolidinediones (TZDs) and metformin as first-line therapy draws from
the algorithm proposed by Wyne et al. [118]. Garber et al. [120] reported that Initial combination
treatment with glyburide/metformin tablets produces greater improvements in glycemic
control than either glyburide or metformin monotherapy.
The goal for glucose control is shown in Table 2 [11, 121]. Stimulating insulin secretion and
minimizing insulin resistance both have the potential to bring a patient to goal, but it is
theorized that bringing a patient to goal by reducing insulin resistance is more likely to reduce
the macro-vascular complications and cardiovascular risks.
Based on several long-term, prospective studies which showed the significant reductions in
cardiovascular risks associated with diabetes, the American Diabetes Association and Amer‐
ican Association of Clinical Endocrinologists set forth standards and guidelines for the medical
management of diabetes [11]. The recommendations clearly outline a multifactorial plan for
managing diabetes and reducing complications [11], but they do not provide specific recom‐
mendations for selection and titration of pharmacological treatment. Pharmacological
treatment for glucose control aims to reduce cardiovascular risk and to delay diabetic com‐
plications.
Lifestyle Modification in Type 2 Diabetes
http://dx.doi.org/10.5772/56377
369
Pharmacological treatment for the management of obesity is primarily aimed at weight loss,
weight loss maintenance and cardiovascular risk reduction. Anti-obesity agents decrease
appetite, reduce absorption of fat or increase energy expenditure. Recently, anti-obesity drugs
such as orlistat, sibtramine and rimonabant have been developed and placed on markets,
however, the latter two were withdrawn from markets in the United States, Europe and
Australia due to serious adverse events including psychiatric and cardiovascular related
concerns. Recently, contrave, a combination of two approved drugs of bupropion and
naltrexone, completed Phase III trials with significant weight loss and was approved by FDA
in 2010, but subsequently the FDA declined to approve contrave due to serious cardiovascular
adverse events in 2011 [122]. A contrave cardiovascular outcome trial, called “Light Study”, is
ongoing and is expected to be completed by the first quarter of 2013. Importantly, obesity is,
at least, in part, determined by genetic backgrounds [123], suggesting that a genetic approach
to limiting obesity may find a place in the future.
7.3. Bariatric surgery
Gastric bypass and adjustable gastric banding are the two most commonly performed bariatric
procedures for the treatment of morbid obesity or obesity which is resistant to lifestyle
modification such as a low caloric diet plus exercise. Multiple mechanisms contribute to the
improved glucose metabolism seen after bariatric surgery, including caloric restriction,
changes in the enteroinsular axis, alterations in the adipoinsular axis, release of nutrient-
stimulated hormones from endocrine organs, stimulation from the nervous system, and
psychosocial aspects including a dramatic improvement in quality of life [124]. Dixon et al. [86,
125] showed that gastric banding induced significant weight loss and resulted in better glucose
control and less need for diabetes medication than conventional approaches to weight loss and
diabetes control in a randomized controlled study in obese subjects with recently diagnosed
type 2 diabetes. Koshy et al.[124] and other investigators [126, 127] compared the effects on
weight loss, mortality, morbidity and changes in quality of life in subjects with either gastric
bypass or gastric banding. The percent of excess weight loss at 4 years was higher in the gastric
Glycemic control A1C goal of < 7.0% Measure every 3 months
Blood pressure control < 130/80 mmHg Every visit
Lipid control LDL < 70 mg/dl† Measure yearly or
Triglycerides < 150 mg/dl more frequently
HDL > 45 mg/dl if goals are not met
Urine protein Microalbuminuria <30 mg/24 hours Measure yearly
*American Diabetes Association Standards of medical care for patients with diabetesmellitus. Diabetes Care 26
(Suppl.):S33–S50, 2003.
†National Cholesterol Education Program: Implications of clinical trials for the ATP
Table 2. Diabetes Control Goals (by American Diabetes Association) Goals Endpoints Assessment
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bypass group compared to the gastric banding group. Postoperative HOMA-IR correlated
with % weight loss [126]. Concurrent with restoration of insulin sensitivity and decreases in
plasma leptin were dramatic decreases in skeletal muscle at 3 and 9 months after gastric
banding and a significant decrease in peroxisome proliferation activated receptor-alpha-
regulated genes at 9 months. Gumbs et al. [128] speculated that a decrease in fat mass after
bariatric surgery significantly affected circulating adipocytokines, which favourably influ‐
enced insulin resistance. Improvements in glucose metabolism and insulin resistance follow‐
ing bariatric surgery occur, in the short-term from decreased stimulation of the entero-insular
axis by restricted calorie intake and in the long-term by decreased release of adipocytokines
due to reduced fat mass. Leptin levels drop and adiponectin levels rise following laparoscopic
adjustable gastric banding and gastric bypass. These changes correlate with weight loss and
improvement in insulin sensitivity [128].
All  forms of  weight  loss  surgery  lead to  calorie  restriction,  weight  loss,  decrease  in  fat
mass, and improvement in insulin resistance, type 2 diabetes mellitus, obesity and obesi‐
ty-related  hypertension  [127].  Left  ventricular  relaxation  impairment,  assessed  by  tissue
Doppler  imaging,  normalized 9  months after  surgery [129].  Laparoscopic  gastric  bypass
and gastric  banding are both safe  and effective approaches for  the treatment of  morbid
obesity,  but  gastric  bypass  surgery  seems to  exert  a  better  early  weight  loss  and more
rapid  ameliorative  effects  on  insulin  resistance  and  adipocytokines,  muscle  metabolism
and left ventricular function.
8. Conclusion
The prevalence of diabetes, especially type 2 diabetes and hypertension are significantly
increased due, at least in part, to the increased prevalence of obesity. Type 2 diabetes is
frequently associated with obesity, and is an important risk factor for cardiovascular morbidity
and mortality and cardiac- and renal complications. Type 2 diabetes, hypertension and obesity
are characterized by stimulation of the renin-angiotensin-aldosterone system (RAAS), elevated
sympathetic activity and insulin resistance. Importantly, these characteristics, themselves,
confer cardiovascular risk. Therefore, treatments for type 2 diabetes should be selected from
favourable effects on stimulated RAAS, elevated sympathetic nervous system activity, insulin
and leptin resistance.
Weight loss is recommended as the first line of treatment for type 2 diabetes and hyper‐
tension associated with type 2 diabetes in obesity. Lifestyle modification such as a caloric
restricted diet,  reducing sedentary behaviour and increases in exercise form the basis of
all  therapy.  Weight  loss  treated  with  lifestyle  modification  including  calorie  restriction
and/or exercise causes normalization of stimulated RAAS, sympathetic activation, insulin
resistance,  and hyperleptinemia.  Recently,  Masuo et  al.  [5]  and Straznicky et  al.  [4]  have
shown that  low caloric  diet  and exercise have different effects  on insulin resistance,  the
RAAS, and sympathetic nervous activity in obese hypertensive subjects, even though sim‐
ilar  weight  loss  was  observed.  Exercise  had  stronger  effects  on  normalizing  the  RAAS
Lifestyle Modification in Type 2 Diabetes
http://dx.doi.org/10.5772/56377
371
stimulation, sympathetic activation and insulin resistance compared to diet only. The ob‐
servations demonstrate that a combination therapy for weight loss with a low caloric diet
and exercise is  recommended for weight loss due to stronger suppression of  insulin re‐
sistance and sympathetic activation, which both, themselves, are known as risk factors for
cardiovascular  events.  Although  few  studies  have  observed  changes  in  body  weight,
blood pressure,  RAAS, sympathetic  nervous activity,  insulin resistance and leptin resist‐
ance over a long duration such as more than 2 years, Masuo et al. [6] observed more than
30% individuals who initially succeeded to significantly lose weight, had rebound weight
gain over 2 years. Maintenance of weight loss is another key factor to delay and prevent
type 2 diabetes and to reduce cardiovascular risks in type 2 diabetes in obesity.
In addition, special diets such as a low carbohydrate diet were reported as beneficial on weight
loss previously, but it might cause an increase in cardiac risk. The official statement from
American Heart Association reported that high-protein diet and low carbohydrate diet are not
recommended diets due to increases in cardiovascular risk.
Gastric bypass and adjustable gastric banding are the two most commonly performed bariatric
procedures for the treatment of morbid obesity or obesity which is resistant to lifestyle
modification such as a low caloric diet plus exercise. Weight loss by bariatric surgery leads to
improvement or normalization of glucose metabolisms from multiple mechanisms including
caloric restriction, changes in the enteroinsular axis, alterations in the adipoinsular axis, release
of nutrient-stimulated hormones from endocrine organs, stimulation from the nervous system,
and psychosocial aspects including a dramatic improvement in quality of life.
Understanding the mechanisms underlying type 2 diabetes in obesity may help to achieve
weight loss and maintenance of weight loss and resultant better control on type 2 diabetes,
and delay and prevent the onset of type 2 diabetes or reduce complications.
This review provides information regarding, i) the importance of lifestyle medication on type
2 diabetes in obesity, ii) different effects of lifestyle modifications on weight loss and neuro‐
hormonal parameters between diet and exercise, and iii) the mode of weight loss and how it
influences different physiological pathways. Different mechanisms may contribute to control
in blood glucose levels and blood pressure and cardiovascular risks associated with weight
loss with the relevant physiological mechanisms at play being dependent on the mode of
weight loss.
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